Skip to main content

Table 3 Evaluation of risk factors for hyperinfection and disseminated infection

From: Implementation and evaluation of a quality and safety tool for ambulatory strongyloidiasis patients at high risk of adverse outcome

Risk factor screened by specific testing or evaluated based on history and physical examination Pre-implementation (n = 26) Post-implementation (n = 11) p-valuea
Immunosuppressive drug (%)
 Yes 26 (100.0) 11 (100.0)  
 No 0 (0.0) 0 (0.0)  
HTLV-1 b (%)
 Yes 8 (30.8) 8 (80.0)  
 No 18 (69.2) 2 (20.0) 0.011
HIV c (%)
 Yes 11 (42.3) 7 (70.0)  
 No 15 (57.7) 3 (30.0) 0.264
Neoplasms (%)
 Yes 26 (100.0) 11 (100.0)  
 No 0 (0.0) 0 (0.0) –
Upcoming or current organ transplant (%)
 Yes 26 (100.0) 11 (100.0)  
 No 0 (0.0) 0 (0.0) –
Diabetes mellitus (%)
 Yes 26 (100.0) 11 (100.0)  
 No 0 (0.0) 0 (0.0) –
End-stage renal disease (%)
 Yes 26 (100.0) 11 (100.0)  
 No 0 (0.0) 0 (0.0) –
Peripheral or unexplained eosinophilia (%)
 Yes 25 (96.2) 10 (90.9)  
 No 1 (3.8) 1 (9.1) 0.512
Drug-drug interaction with prescribed therapy, where patient taking at least 1 other prescription medication (%)
 Yes 3 (11.5) 4 (36.3)  
 No 9 (34.6) 2 (18.2)  
 Not applicable 14 (53.8) 5 (45.5) 0.272
Country of birth (%)
 Yes 20 (76.9) 11 (100)  
 No 6 (23.1) 0 (0) 0.151
  1. ap-values are not applicable for results that cannot be compared
  2. bOne patient not applicable in the post-implementation group
  3. cOne patient not applicable in the post-implementation group
Back to article page

Tropical Diseases, Travel Medicine and Vaccines

ISSN: 2055-0936

Contact us